High Grade Glioma
Conditions
Keywords
interventions of physical activity and exercising (PAE), resistance training, endurance training
Brief summary
To investigate the influence of two physical activity and exercising (PAE) interventions, namely resistance training and endurance training in relation to quality of life, depression, fatigue, sleep, anxiety, stress and coping, body image, and social interactions (psychological dimensions); cardiorespiratory fitness, morning cortisol secretion, inflammatory markers, and objective sleep (physiological dimensions), along with cancer-related dimensions
Detailed description
Patients with high grade glioma (WHO III° and IV°) and undergoing radiotherapy, chemotherapy, or both radio- and chemotherapy suffer from decreased quality of life (QoL). This study is to analyse the influence of two adjuvant interventions of physical activity and exercising (PAE) (namely resistance training and endurance training) in relation to quality of life, depression, fatigue, sleep, anxiety, stress and coping, body image, and social interactions (psychological dimensions); cardiorespiratory fitness, morning cortisol secretion, inflammatory markers, and objective sleep (physiological dimensions).
Interventions
OTHERendurance training
physical activity and exercising (PAE)
OTHERsocial support and counseling
social support and counseling
OTHERresistance training
physical activity and exercising (PAE)
Sponsors
University Basel, Department of Sport, Exercise and Health, Division of Sport Science and Psychosocial Health
University Hospital, Basel, Switzerland
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with high grade glioma (WHO III° and IV°), and undergoing radiotherapy, chemotherapy, or both * Willing and able to follow the study intervention * Signed written informed consent
Exclusion criteria
* Severe psychiatric (psychosis, suicidal behavior, substance use disorder) and somatic comorbidities (severe cardiovascular disease, severe diabetes, impairments of the musculo-skeletal system) * patients not willing or able anymore to follow the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Grip force | Baseline and week 3 and week 6 | Maximum isometric grip force of the dominant hand is assessed using the hand dynamometer. Participants make three attempts. Mean outcomes is compared to reference data |
| Change in Mental Toughness Questionnaire (MTQ48) | Baseline and week 3 and week 6 | The 48 item MTQ48 measures the subcomponents challenge, commitment, emotional and life control, and interpersonal confidence and confidence in ability. Answers are given on five-point Likert-type scales ranging from 1 (=strongly disagree) to 5 (=strongly agree), with higher scores reflecting greater MT |
| Change in International Physical Activity Questionnaire | Baseline and week 3 and week 6 | questionnaire consists of several items and asks about the amount of days with walking, moderate and vigorous physical activity. |
| Change in submaximal 6-min walking test (6MWT) | Baseline and week 3 and week 6 | To assess functional exercise capacity, distance walked during 6 min will be assessed and compared to reference age and gender norms |
| Change in Intolerance of Uncertainty Scale (IU) | Baseline and week 3 and week 6 | IU: 5-point rating scale (1 = not at all characteristic of me, 5 = entirely characteristic of me) indicating how much patient agrees with the item. The higher the overall score is, the more the respondent is assumed to be more intolerant of uncertainty |
| Change in Insomnia Severity Index (ISI) | Baseline and week 3 and week 6 | ISI is a 7-item screening measure for insomnia. Items answered on 5-point rating scales (0 = not at all, 4 = very much) |
| Change in Functional Assessment of Cancer Therapy Scale (FACT) | Baseline and week 3 and week 6 | Cancer-related Quality of Life (QOL) assessed by Functional Assessment of Cancer Therapy Scale (FACT), a self-report instrument which measures multidimensional QOL. The FACT evaluation system uses a 29-49 item compilation of a generic core and numerous subscales (9-20 items each) which reflect symptoms associated with different diseases, symptom complexes and treatments. |
| Change in Hamilton Depression Rating Scale (HDRS) | Baseline and week 3 and week 6 | HDRS scale to assess patients' severity of Depression (mood, feelings of guilt, suicide ideation, insomnia, agitation or retardation, anxiety, weight loss, and somatic symptoms); each item on the questionnaire is scored on a 3 or 5 point scale; a score of 0-7 is considered to be normal |
| Change in Perceived Stress Scale (PSS) | Baseline and week 3 and week 6 | General perceived stress is assessed with the 10-item Perceived Stress Scale (PSS). The PSS measures the degree to which respondents find their lives unpredictable, uncontrollable and overloading. Answers were given on a five-point Likert-type scale anchored at 1 (never) to 5 (very often). Four items were reverse scored. The mean was calculated in order to obtain an overall score. |
| Change in Fatigue Severity Scale | Baseline and week 3 and week 6 | nine items, and answers are given on seven-point rating scales ranging from 1 (not at all) to 7 (definitively/almost always), with higher mean scores reflecting greater fatigue |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in sleep continuity assessed by EEG | Baseline and week 6 | Sleep is objectively assessed via an easy-to-use in-home sleep-EEG. It consists of three electrodes and measures sleep continuity (awakenings after sleep onset: number of duration of awakenings) |
| Change in sleep architecture (min; %) | Baseline and week 6 | Sleep is objectively assessed via an easy-to-use in-home sleep-EEG. It consists of three electrodes and measures sleep architecture (wake, Non-rapid eye movement (REM)- sleep stages 1-4 (min; %); REM-sleep (min; %). |
| Change in C reactive protein (CRP) (mg/l) | Baseline and week 6 | blood samples are taken before and after the 6MWT and grip force test to assess inflammatory marker CRP (mg/l) |
Countries
Switzerland
Outcome results
None listed